Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.
作者信息
Rangachari Deepa, Le Xiuning, Shea Meghan, Huberman Mark S, VanderLaan Paul A, Kobayashi Susumu S, Costa Daniel B
机构信息
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
出版信息
J Thorac Oncol. 2017 Nov;12(11):e175-e177. doi: 10.1016/j.jtho.2017.06.002. Epub 2017 Jun 10.
Abstract
摘要
相似文献
1
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.以克唑替尼作为初始精准治疗实现5年无进展生存的ALK重排肺癌病例
J Thorac Oncol. 2017 Nov;12(11):e175-e177. doi: 10.1016/j.jtho.2017.06.002. Epub 2017 Jun 10.
2
[Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].[克唑替尼：终于用于晚期ALK重排非小细胞肺癌的一线治疗]
Bull Cancer. 2016 Feb;103(2):125-6. doi: 10.1016/j.bulcan.2015.12.002. Epub 2016 Jan 25.
3
Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.克唑替尼和阿来替尼序贯治疗ALK重排阳性非小细胞肺癌患者的无进展生存期和总生存期
Clin Lung Cancer. 2016 Nov;17(6):528-534. doi: 10.1016/j.cllc.2016.05.001. Epub 2016 May 18.
4
ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?对克唑替尼有反应的ALK重排鳞状细胞肺癌：非小细胞肺癌领域中缺失的环节？
Lung Cancer. 2016 Jan;91:67-9. doi: 10.1016/j.lungcan.2015.11.010. Epub 2015 Nov 10.
5
Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.神经内分泌表型作为ALK重排肺腺癌的一种获得性耐药机制。
Lung Cancer. 2016 Feb;92:15-8. doi: 10.1016/j.lungcan.2015.12.001. Epub 2015 Dec 4.
6
Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.间变性淋巴瘤激酶（ALK）重排腺癌组织学转化为小细胞肺癌：一种对ALK抑制剂耐药的新机制。
Lung Cancer. 2016 Dec;102:38-41. doi: 10.1016/j.lungcan.2016.10.012. Epub 2016 Oct 27.
7
Treatment and detection of ALK-rearranged NSCLC.ALK 重排非小细胞肺癌的治疗与检测。
Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12.
8
Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.克唑替尼治疗ALK重排转移性非小细胞肺癌脑转移的有效给药方案。
J Thorac Oncol. 2013 Dec;8(12):e112-3. doi: 10.1097/JTO.0000000000000038.
9
Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.一名肺腺癌患者经ALK免疫组化鉴定存在ALK 2p23融合，其脉络膜转移灶对克唑替尼治疗有反应。
J Thorac Oncol. 2013 Dec;8(12):e109-11. doi: 10.1097/01.JTO.0000437502.82078.9b.
10
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.克唑替尼治疗晚期ALK重排非小细胞肺癌合并脑转移患者的临床经验
J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26.
引用本文的文献
1
A Real-World Study of Patient Characteristics and Clinical Outcomes in Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.一线奥希替尼治疗突变型肺癌患者特征及临床结局的真实世界研究：将 FLAURA 试验结果扩展至常规临床实践
Cancers (Basel). 2024 Mar 7;16(6):1079. doi: 10.3390/cancers16061079.
2
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).ALK 易位型晚期非小细胞肺癌患者的临床特征及克唑替尼（CRIZOLONG GFPC 05-19 研究）的长期疗效。
Target Oncol. 2023 Nov;18(6):905-914. doi: 10.1007/s11523-023-01014-z. Epub 2023 Nov 15.
3
ALK‑positive locally advanced lung cancer in a patient who achieved long‑term complete response with crizotinib: A case report.一名使用克唑替尼获得长期完全缓解的ALK阳性局部晚期肺癌患者：病例报告
Exp Ther Med. 2022 Sep 2;24(5):650. doi: 10.3892/etm.2022.11587. eCollection 2022 Nov.
4
Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib.克唑替尼或艾乐替尼治疗的非小细胞肺癌中枢神经系统进展的特征。
Cancer Rep (Hoboken). 2021 Dec;4(6):e1414. doi: 10.1002/cnr2.1414. Epub 2021 May 7.
5
Long-term complete response in a patient with postoperative recurrent -rearranged lung adenocarcinoma treated with crizotinib: A case report.克唑替尼治疗术后复发且发生重排的肺腺癌患者的长期完全缓解：一例报告
Mol Clin Oncol. 2019 Sep;11(3):309-312. doi: 10.3892/mco.2019.1892. Epub 2019 Jul 3.
6
From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.从希望到现实：免疫检查点抑制剂为晚期肺癌带来持久总生存期
J Clin Oncol. 2019 Oct 1;37(28):2511-2513. doi: 10.1200/JCO.19.01207. Epub 2019 Jun 2.
7
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.IV 期 ALK 重排非小细胞肺癌的自然病史及与总生存相关的因素。
J Thorac Oncol. 2019 Apr;14(4):691-700. doi: 10.1016/j.jtho.2018.12.014. Epub 2018 Dec 30.
8
TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.在肺癌中，当TP53突变与ALK重排同时出现时，具有预测和预后价值。
Ann Oncol. 2018 Oct 1;29(10):2028-2030. doi: 10.1093/annonc/mdy339.
9
Tumor biomarker testing in non-small-cell lung cancer: A decade of change.非小细胞肺癌的肿瘤标志物检测：十年变迁。
Lung Cancer. 2018 Feb;116:90-95. doi: 10.1016/j.lungcan.2018.01.002. Epub 2018 Jan 4.
10
Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.在晚期肺癌治疗中，将更有效且毒性更小的治疗方案前移至一线治疗。
J Thorac Dis. 2017 Sep;9(9):2812-2818. doi: 10.21037/jtd.2017.08.79.
本文引用的文献
1
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.阿来替尼用于ALK阳性、克唑替尼耐药的非小细胞肺癌：一项单组、多中心、2期试验。
Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19.
2
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.接受克唑替尼和色瑞替尼序贯治疗的ALK阳性非小细胞肺癌患者的无进展生存期和总生存期
Clin Cancer Res. 2015 Jun 15;21(12):2745-52. doi: 10.1158/1078-0432.CCR-14-3009. Epub 2015 Feb 27.
3
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.克唑替尼治疗晚期ALK重排非小细胞肺癌合并脑转移患者的临床经验
J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26.
4
Ceritinib in ALK-rearranged non-small-cell lung cancer.塞瑞替尼治疗间变性淋巴瘤激酶重排的非小细胞肺癌。
N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107.
5
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.间变性淋巴瘤激酶抑制在非小细胞肺癌中的作用。
N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448.
Zotero 插件